These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 27232281)
1. Potential diagnostic and prognostic biomarkers for cholangiocarcinoma in serum and bile. Wang B; Chen L; Chang HT Biomark Med; 2016 Jun; 10(6):613-9. PubMed ID: 27232281 [TBL] [Abstract][Full Text] [Related]
2. High Bile Titer and High Bile to Serum Ratio of CYFRA 21 - 1 Reliably Discriminate Malignant Biliary Obstruction Caused by Cholangiocarcinoma. Chen J; Liang J; Xu B; Liang J; Ma M; Wang Z; Zeng G; Xu Q; Liang L; Lai J; Huang L J Gastrointest Cancer; 2024 Jun; 55(2):800-808. PubMed ID: 38280173 [TBL] [Abstract][Full Text] [Related]
3. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study. Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272 [TBL] [Abstract][Full Text] [Related]
4. Serum markers of intrahepatic cholangiocarcinoma. Malaguarnera G; Paladina I; Giordano M; Malaguarnera M; Bertino G; Berretta M Dis Markers; 2013; 34(4):219-28. PubMed ID: 23396291 [TBL] [Abstract][Full Text] [Related]
5. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma. Huang L; Chen W; Liang P; Hu W; Zhang K; Shen S; Chen J; Zhang Z; Chen B; Han Y; Meng F; DeMorrow S; Yin X; Lai J; Liang L Dig Dis Sci; 2015 May; 60(5):1273-83. PubMed ID: 25487191 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Tumor Markers and Their Impact on Prognosis in Gallbladder, Bile Duct and Cholangiocellular Carcinomas - A Pilot Study. Liska V; Treska V; Skalicky T; Fichtl J; Bruha J; Vycital O; Topolcan O; Palek R; Rosendorf J; Polivka J; Holubec L Anticancer Res; 2017 Apr; 37(4):2003-2009. PubMed ID: 28373474 [TBL] [Abstract][Full Text] [Related]
7. Recent developments in the research on biomarkers of cholangiocarcinoma in primary sclerosing cholangitis. Wannhoff A; Gotthardt DN Clin Res Hepatol Gastroenterol; 2019 Jun; 43(3):236-243. PubMed ID: 30266579 [TBL] [Abstract][Full Text] [Related]
8. Circulating Biomarkers for Cholangiocarcinoma. Loosen SH; Vucur M; Trautwein C; Roderburg C; Luedde T Dig Dis; 2018; 36(4):281-288. PubMed ID: 29807369 [TBL] [Abstract][Full Text] [Related]
9. Total serum bile acid as a potential marker for the diagnosis of cholangiocarcinoma without jaundice. Sombattheera S; Proungvitaya T; Limpaiboon T; Wongkham S; Wongkham C; Luvira V; Proungvitaya S Asian Pac J Cancer Prev; 2015; 16(4):1367-70. PubMed ID: 25743800 [TBL] [Abstract][Full Text] [Related]
10. Proteomics analysis and evaluation of biomarkers for detection of cholangiocarcinoma. Sriwanitchrak P; Viyanant V; Chaijaroenkul W; Srivatanakul P; Gram HR; Eursiddhichai V; Na-Bangchang K Asian Pac J Cancer Prev; 2011; 12(6):1503-10. PubMed ID: 22126489 [TBL] [Abstract][Full Text] [Related]
11. Significance of S100P as a biomarker in diagnosis, prognosis and therapy of opisthorchiasis-associated cholangiocarcinoma. Wu Z; Boonmars T; Nagano I; Boonjaraspinyo S; Srinontong P; Ratasuwan P; Narong K; Nielsen PS; Maekawa Y Int J Cancer; 2016 Jan; 138(2):396-408. PubMed ID: 26312563 [TBL] [Abstract][Full Text] [Related]
12. Identification of bile survivin and carbohydrate antigen 199 in distinguishing cholangiocarcinoma from benign obstructive jaundice. Liu Y; Sun J; Zhang Q; Jin B; Zhu M; Zhang Z Biomark Med; 2017 Jan; 11(1):11-18. PubMed ID: 27874286 [TBL] [Abstract][Full Text] [Related]
13. Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma. Wang LJ; Zhang KL; Zhang N; Ma XW; Yan SW; Cao DH; Shi SJ Oncotarget; 2015 Jul; 6(21):18631-40. PubMed ID: 26087181 [TBL] [Abstract][Full Text] [Related]
14. Peptidase inhibitor 15 as a novel blood diagnostic marker for cholangiocarcinoma. Jiang Y; Zheng X; Jiao D; Chen P; Xu Y; Wei H; Qian Y EBioMedicine; 2019 Feb; 40():422-431. PubMed ID: 30638862 [TBL] [Abstract][Full Text] [Related]
15. Serum and bile biomarkers for cholangiocarcinoma. Alvaro D Curr Opin Gastroenterol; 2009 May; 25(3):279-84. PubMed ID: 19396965 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic biomarkers in cholangiocarcinoma. Macias RIR; Kornek M; Rodrigues PM; Paiva NA; Castro RE; Urban S; Pereira SP; Cadamuro M; Rupp C; Loosen SH; Luedde T; Banales JM Liver Int; 2019 May; 39 Suppl 1():108-122. PubMed ID: 30843325 [TBL] [Abstract][Full Text] [Related]
17. Molecular Biomarkers in Cholangiocarcinoma: Focus on Bile. Dolbnya AD; Popov IA; Pekov SI Curr Top Med Chem; 2024; 24(8):722-736. PubMed ID: 38303538 [TBL] [Abstract][Full Text] [Related]
18. Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker. Chiang KC; Yeh TS; Wu RC; Pang JS; Cheng CT; Wang SY; Juang HH; Yeh CN Sci Rep; 2016 Oct; 6():36138. PubMed ID: 27782193 [TBL] [Abstract][Full Text] [Related]
19. A Novel Serum Glycobiomarker for Diagnosis and Prognosis of Cholangiocarcinoma Detected by Teeravirote K; Luang S; Waraasawapati S; Boonsiri P; Wongkham C; Wongkham S; Silsirivanit A Molecules; 2021 May; 26(9):. PubMed ID: 34066878 [TBL] [Abstract][Full Text] [Related]
20. Improve discrimination power of serum markers for diagnosis of cholangiocarcinoma using data mining-based approach. Pattanapairoj S; Silsirivanit A; Muisuk K; Seubwai W; Cha'on U; Vaeteewoottacharn K; Sawanyawisuth K; Chetchotsak D; Wongkham S Clin Biochem; 2015 Jul; 48(10-11):668-73. PubMed ID: 25863112 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]